Raza Ali, Chohan Tahir Ali, Sarfraz Muhammad, Chohan Talha Ali, Imran Sajid Muhammad, Tiwari Rakesh Kumar, Ansari Siddique Akber, Alkahtani Hamad M, Yasmeen Ansari Shabana, Khurshid Umair, Saleem Hammad
College of Pharmacy, The University of Lahore, Lahore, Pakistan.
Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan.
J Biomol Struct Dyn. 2023;41(23):14358-14371. doi: 10.1080/07391102.2023.2187638. Epub 2023 Mar 10.
Fibroblast growth factor receptors 1 (FGFR1) is an emerging target for the development of anticancer drugs. Uncontrolled expression of FGFR1 is strongly associated with a number of different types of cancers. Apart from a few FGFR inhibitors, the FGFR family members have not been thoroughly studied to produce clinically effective anticancer drugs. The application of proper computational techniques may aid in understanding the mechanism of protein-ligand complex formation, which may provide a better notion for developing potent FGFR1 inhibitors. In this study, a variety of computational techniques, including 3D-QSAR, flexible docking and MD simulation followed by MMGB/PBSA, H-bonds and distance analysis, have been performed to systematically explore the binding mechanism of pyrrolo-pyrimidine derivatives against FGFR1. The 3D-QSAR model was generated to deduce the structural determinants of FGFR1 inhibition. The high and values for the CoMFA and CoMSIA models indicated that the created 3D-QSAR models could reliably predict the bioactivities of FGFR1 inhibitors. The computed binding free energies (MMGB/PBSA) for the selected compounds were consistent with the ranking of their experimental binding affinities against FGFR1. Furthermore, per-residue energy decomposition analysis revealed that the residues Lys514 in catalytic region, Asn568, Glu571 in solvent accessible portion and Asp641 in DFG motif exhibited a strong tendency to mediate ligand-protein interactions through the hydrogen bonding and interactions. These findings may benefit researchers in gaining better knowledge of FGFR1 inhibition and may serve as a guideline for the development of novel and highly effective FGFR1 inhibitors.Communicated by Ramaswamy H. Sarma.
成纤维细胞生长因子受体1(FGFR1)是抗癌药物开发中一个新兴的靶点。FGFR1的失控表达与多种不同类型的癌症密切相关。除了少数FGFR抑制剂外,FGFR家族成员尚未得到充分研究以开发出临床有效的抗癌药物。应用适当的计算技术可能有助于理解蛋白质 - 配体复合物形成的机制,这可能为开发有效的FGFR1抑制剂提供更好的思路。在本研究中,进行了多种计算技术,包括3D-QSAR、柔性对接和MD模拟,随后进行MMGB/PBSA、氢键和距离分析,以系统地探索吡咯并嘧啶衍生物与FGFR1的结合机制。生成3D-QSAR模型以推断FGFR1抑制的结构决定因素。CoMFA和CoMSIA模型的高 和 值表明所创建的3D-QSAR模型能够可靠地预测FGFR1抑制剂的生物活性。所选化合物的计算结合自由能(MMGB/PBSA)与其对FGFR1的实验结合亲和力排名一致。此外,每个残基的能量分解分析表明,催化区域的Lys514残基、溶剂可及部分的Asn568、Glu571残基以及DFG基序中的Asp641残基表现出通过氢键和 相互作用介导配体 - 蛋白质相互作用的强烈倾向。这些发现可能有助于研究人员更好地了解FGFR1抑制作用,并可为开发新型高效FGFR1抑制剂提供指导。由Ramaswamy H. Sarma传达。